La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Emyria Résultats passés
Passé contrôle des critères 0/6
Emyria's earnings have been declining at an average annual rate of -20.9%, while the Pharmaceuticals industry saw earnings growing at 35.6% annually. Revenues have been declining at an average rate of 0.7% per year.
Informations clés
-20.9%
Taux de croissance des bénéfices
-1.6%
Taux de croissance du BPA
Pharmaceuticals Croissance de l'industrie | 31.2% |
Taux de croissance des recettes | -0.7% |
Rendement des fonds propres | -1,258.1% |
Marge nette | -613.0% |
Dernière mise à jour des bénéfices | 31 Dec 2023 |
Mises à jour récentes des performances passées
Recent updates
Will Emyria (ASX:EMD) Spend Its Cash Wisely?
Feb 02We're Hopeful That Emyria (ASX:EMD) Will Use Its Cash Wisely
May 20Here's Why We're Not Too Worried About Emyria's (ASX:EMD) Cash Burn Situation
Oct 20We Think Emyria (ASX:EMD) Needs To Drive Business Growth Carefully
Jun 11Will Emyria (ASX:EMD) Spend Its Cash Wisely?
Feb 25Need To Know: Emyria Limited (ASX:EMD) Insiders Have Been Buying Shares
Nov 17Ventilation des recettes et des dépenses
Comment Emyria gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
---|---|---|---|---|
31 Dec 23 | 2 | -12 | 2 | 0 |
30 Sep 23 | 2 | -9 | 2 | 0 |
30 Jun 23 | 2 | -5 | 2 | 0 |
31 Mar 23 | 2 | -6 | 2 | 1 |
31 Dec 22 | 2 | -8 | 2 | 2 |
30 Sep 22 | 2 | -7 | 3 | 2 |
30 Jun 22 | 2 | -7 | 3 | 1 |
31 Mar 22 | 2 | -7 | 3 | 1 |
31 Dec 21 | 2 | -6 | 3 | 1 |
30 Sep 21 | 2 | -6 | 2 | 1 |
30 Jun 21 | 2 | -5 | 2 | 1 |
31 Mar 21 | 2 | -5 | 2 | 1 |
31 Dec 20 | 2 | -5 | 1 | 1 |
30 Sep 20 | 1 | -5 | 2 | 1 |
30 Jun 20 | 1 | -5 | 2 | 1 |
31 Mar 20 | 1 | -5 | 2 | 1 |
31 Dec 19 | 1 | -4 | 2 | 0 |
30 Sep 19 | 0 | -3 | 2 | 0 |
30 Jun 19 | 0 | -3 | 1 | 0 |
Des revenus de qualité: EMD is currently unprofitable.
Augmentation de la marge bénéficiaire: EMD is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: EMD is unprofitable, and losses have increased over the past 5 years at a rate of 20.9% per year.
Accélération de la croissance: Unable to compare EMD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: EMD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.2%).
Rendement des fonds propres
ROE élevé: EMD has a negative Return on Equity (-1258.13%), as it is currently unprofitable.